HC Wainwright Lowers MediWound (NASDAQ:MDWD) Price Target to $25.00

MediWound (NASDAQ:MDWD) had its target price decreased by HC Wainwright from $28.00 to $25.00 in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Separately, StockNews.com raised shares of MediWound to a “sell” rating in a research note on Monday, August 5th.

MediWound Stock Up 0.1 %

Shares of MDWD opened at $17.47 on Wednesday. The business’s fifty day moving average is $17.16 and its 200 day moving average is $17.38. MediWound has a 12-month low of $8.75 and a 12-month high of $24.00. The stock has a market cap of $188.43 million, a P/E ratio of -6.02 and a beta of 0.83.

Hedge Funds Weigh In On MediWound

Several large investors have recently bought and sold shares of the stock. Investor AB bought a new stake in shares of MediWound in the 3rd quarter worth $15,750,000. Rosalind Advisors Inc. grew its position in MediWound by 22.3% in the 3rd quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after purchasing an additional 114,560 shares in the last quarter. ARK Investment Management LLC purchased a new stake in MediWound in the 3rd quarter valued at about $1,806,000. State Street Corp lifted its position in shares of MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after buying an additional 45,529 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of MediWound in the 2nd quarter worth approximately $342,000. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.